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Background: Stigmatic attitudes towards people with the
diagnosis of mental illness are widespread in the general
public [1] and are the major obstacle for successful treat-
ment, rehabilitation and reintegration of patients into the
society [2]. Given the magnitude of this issue, and in the
effort to develop effective anti stigma intervention pro-
grams, trend analysis studies were conducted, examining the
changes in attitudes over the years [3]. The construct of
social distance, which involves the desire to avoid contact
with a particular group of people was commonly used to
assess stigma. These studies have consistently reported that
despite the improvement in mental health literacy of the
public, social distance preferences concerning mentally ill
patients have not changed over the last 20 years, and in some
cases have even increased [3]. However, the number of
studies using trend analysis is scarce and mainly limited to
wealthier countries because such studies are both costly and
time intensive. Consequently, most studies to date have been
carried out in North Western Europe whereas data from
Central and Eastern European countries, especially from
former communist countries, is lacking [4,5].
Objective: In the face of underﬁnanced mental health system
and the lack of any national anti-stigma programs or research,
the aim of this study is to shed light into mental illness stigma
in Hungary. More speciﬁcally, this study aimed to explore for
the ﬁrst time, potential changes concerning attitudes of the
Hungarian population towards mentally ill patients.
Method: National representative surveys (N=7605) of
adults aged 18-53 years were carried out in Hungary in
2001, 2003, 2007 and 2015. An interview was conducted,
asking for socio-demographic information and participants'
desire for social distance from mentally ill patients, mea-
sured by Bogardus social distance scale. In order to put into
context the stigmatic attitudes towards mentally ill
patients, participants were also asked to report on theirsocial distance preferences towards other minorities in the
Hungarian society. Trend analysis was performed to examine
the trends of social distance.
Results: Time-trend analysis indicated a signiﬁcant (posi-
tive) trend in public preferences for social distance towards
more accepting attitudes during the years of 2001-2015.
However, closer examination reveals that the effect size is
very small (0.05) and the 2015 rejection level is still high
(57%) compared to over 60% in both 2001 and 2003. More-
over, during a period of 15 years, mentally ill patients are
among the three most rejected groups in the society (with
only alcoholics and drug users being more rejected).
Conclusions: As was found in other countries around the
world, in Hungary as well, stigmatic attitudes towards men-
tally ill patients are highly prevalent, and have not changed
over the last decade. While stressing a worrisome reality in
Hungary, where no efforts to tackle mental illness stigma were
done, this study also veriﬁes the enormity of the stigma
phenomenon. It is evident, maybe more than anything, that
much effort is needed in Hungary, but also worldwide, in order
to understand and defeat mental illness stigma.
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Background: Major depressive disorder is a high-preva-
lence disease associated with a heavy burden on both
personal well-being and socio-economical welfare, partly
as a result of lacking tailored treatment options [1].
Common single nucleotide polymorphisms (SNPs) were esti-
mated to account for 0.42 of the variance in antidepressant
response [2], conﬁrming the hypothesis that genetic poly-
morphisms may be used as effective markers to provide
tailored antidepressant treatments. Candidate gene and
genome-wide analyses can provide a complementary strat-
egy, since the former can be applied to clarify the role of
SNPs with high pre-test probability of association with the
trait and the latter is useful to study the joint effects of a
number of SNPs in a gene or a set of genes [3].
Aim: We applied such a complementary strategy to the
study of eight genes that are very strong candidates with
previous evidence of pleiotropic effect across psychiatric
traits. The genes of interest are involved in the regulation
of neurotransmission (CACNA1C, CACNB2, ANK3), neural
differentiation, synaptic plasticity, adhesion processes and
structural organization (GRM7, TCF4, ITIH3, SYNE1) and
glucocorticoid signaling (FKBP5).
Methods: Three samples with major depressive disorder
(total n=671) were genotyped for 44 SNPs in strong
candidate genes based on biological function and previous
genome-wide association studies (CACNA1C, CACNB2, ANK3,
GRM7, TCF4, ITIH3, SYNE1, FKBP5). Phenotypes were
response/remission after 4 weeks of treatment and treat-
ment-resistant depression (TRD: non response/non remis-
sion to at least two antidepressant treatments). Genome-
wide data from STAR*D were used to replicate ﬁndings for
response/remission (Level 1, n=1409) and TRD (Level 2,
n=620). Pathways including the most promising candidate
genes for involvement in TRD were investigated in STAR*D
Level 2. Top pathway(s) were investigated using machine
learning models.
Results: FKBP5 rs3800373, rs1360780 and rs9470080
showed replicated associations with response, remission or
TRD. CACNA1C SNPs showed contradictory direction of
association across samples. ANK3 rs1049862 AA genotype
showed a replicated association with better outcome. InSTAR*D the best pathway associated with TRD included
CACNA1C (GO:0006942, permutated p=0.15). Neural net-
works and gradient boosted machine showed that indepen-
dent SNPs in this pathway predicted TRD with a mean
sensitivity of 0.83 and speciﬁcity of 0.56 after 10-fold cross
validation repeated 100 times.
Conclusions: FKBP5 polymorphisms should be considered
for inclusion in antidepressant pharmacogenetic tests.
CACNA1C is a good candidate and GO:0006942 includes
several genes coding for ion channels expressed in the
central nervous system and other genes relevant for exci-
tatory mechanisms. CACNB2 and ANK3 showed replicated
associations with phenotypes and further investigations
could help in clarifying their role. This study may pave the
way to the identiﬁcation of sets of genetic predictors in
speciﬁc pathways able to predict the risk of TRD. It is
reasonable to hypothesize a certain degree of variability in
the genetic variants involved in TRD across different
patients, but the involved pathways are expected to be
more stable. Validated genetic markers of TRD could have a
pivotal role in the implementation of targeted antidepres-
sant treatments.
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